Health Ministry issues stem cell therapy advisory
The Union Ministry of Health and Family Welfare has issued an advisory directing all states and Union Territories to strictly enforce the rules governing stem cell research and therapy. The advisory, dated September 16, 2026, asks healthcare establishments, medical professionals and regulatory authorities to prevent unapproved stem cell interventions from being offered as established treatments.
The Ministry has clarified that stem cell therapy can be used as routine clinical care only for diseases and indications included in its approved list. Any treatment outside those approved uses must be regarded as experimental and cannot be promoted as a standard or commercially proven medical service.
Key points:
Only stem cell therapies approved by the Health Ministry may be offered as routine clinical care.
Experimental stem cell interventions cannot be advertised or promoted as proven cures.
Hospitals, clinics and doctors must comply with the applicable research and treatment regulations.
State and district authorities have been directed to monitor clinical establishments and investigate reported violations.
Stem cell therapy for autism remains experimental
The advisory specifically addresses claims that stem cell therapy can treat Autism Spectrum Disorder. The government has made it clear that the therapeutic use of any type of stem cell for autism is not approved as routine or standard clinical treatment.
Stem cell interventions involving autism may be undertaken only as part of duly approved clinical trials. These studies must follow the National Guidelines for Stem Cell Research, 2017, jointly issued by the Indian Council of Medical Research and the Department of Biotechnology.
Important conditions include:
Stem cell therapy for autism must remain restricted to authorised clinical trials.
The clinical trial must receive all necessary regulatory and ethics approvals.
Clinics cannot market experimental autism interventions as routine medical services.
Doctors cannot claim that stem cells are an established cure for autism.
Parents and caregivers should confirm a trial’s official registration and approvals before considering participation.
The advisory does not prohibit legitimate research but requires it to be conducted under approved clinical-trial safeguards.
NMC warns doctors against unauthorised practices
The National Medical Commission has reinforced the regulatory position through its advisory dated September 5, 2026. It has warned registered medical practitioners against administering, prescribing, recommending, promoting or advertising stem cell therapies for unapproved indications.
The NMC has stated that involvement in unauthorised stem cell treatment could amount to professional misconduct. State Medical Councils have been advised to examine complaints and initiate disciplinary proceedings when violations are established after due process.
The NMC directions cover the following actions:
Administering stem cell therapy for an indication that has not been approved.
Prescribing an experimental intervention as standard treatment.
Promoting unproven therapies through websites, social media or advertisements.
Making unsupported claims about guaranteed recovery or a permanent cure.
Commercially offering stem cell therapy outside an authorised clinical trial.
Failing to properly explain the experimental status and potential risks to patients.
Supreme Court judgment prompted stronger enforcement
The Health Ministry’s advisory follows the Supreme Court’s January 30, 2026 judgment in Yash Charitable Trust and Others versus Union of India and Others. The ruling emphasised that failure to comply with the statutory framework governing stem cell therapy must result in appropriate consequences.
The advisory reminds authorities that the existence of scientific research into stem cells does not permit clinics to sell unapproved interventions. Every therapeutic use must comply with the approved framework, and experimental research must remain within regulated clinical trials.
The judgment and subsequent advisory underline that:
Unapproved stem cell interventions cannot be treated as ordinary medical services.
Regulatory violations must result in meaningful action.
Medical professionals can be investigated for professional misconduct.
Clinical establishments may face penalties or loss of registration.
State authorities are responsible for enforcing the rules at the local level.
Penalties for violating stem cell therapy rules
Doctors found responsible for unauthorised stem cell therapy may face professional-misconduct proceedings under Regulation 7.22 of the Indian Medical Council Regulations, 2002. Any disciplinary action must be taken after examining the evidence and following the required legal process.
Clinical establishments may separately face action under Sections 32 and 40 of the Clinical Establishments Registration and Regulation Act, 2010. Depending on the nature of the violation, this can include financial penalties and cancellation of registration.
Possible consequences include:
Professional-misconduct proceedings against registered medical practitioners.
Disciplinary action by State Medical Councils.
Investigation of hospitals and clinics offering unauthorised treatments.
Penalties under the Clinical Establishments Act.
Cancellation of a clinical establishment’s registration in applicable cases.
Action against misleading promotion or advertisement of unproven therapies.
What patients and families should verify
Patients should not assume that every treatment described as “stem cell therapy” is approved, safe or clinically effective. Before agreeing to any such intervention, they should consult a qualified specialist and verify whether the proposed treatment is authorised for their medical condition.
Patients and families should check:
Whether the proposed stem cell treatment is approved for the diagnosed condition.
Whether it is being offered as standard treatment or as part of a clinical trial.
Whether the clinical trial has valid regulatory and ethics approvals.
Whether the trial is officially registered and provides proper informed-consent documents.
Whether the treating doctor and clinical establishment are appropriately registered.
Whether the clinic is making unsupported claims of guaranteed improvement or cure.
Whether the risks, possible benefits, alternatives and experimental status have been clearly explained.
The advisory’s central message is that stem cell science may hold research potential, but unproven interventions must not be sold as established treatment. Patients should rely on approved medical care and independently verify regulatory claims before making decisions.
Health Ministry issues stem cell therapy advisory
The Union Ministry of Health and Family Welfare has issued an advisory directing all states and Union Territories to strictly enforce the rules governing stem cell research and therapy. The advisory, dated September 16, 2026, asks healthcare establishments, medical professionals and regulatory authorities to prevent unapproved stem cell interventions from being offered as established treatments.
The Ministry has clarified that stem cell therapy can be used as routine clinical care only for diseases and indications included in its approved list. Any treatment outside those approved uses must be regarded as experimental and cannot be promoted as a standard or commercially proven medical service.
Key points:
Only stem cell therapies approved by the Health Ministry may be offered as routine clinical care.
Experimental stem cell interventions cannot be advertised or promoted as proven cures.
Hospitals, clinics and doctors must comply with the applicable research and treatment regulations.
State and district authorities have been directed to monitor clinical establishments and investigate reported violations.
Stem cell therapy for autism remains experimental
The advisory specifically addresses claims that stem cell therapy can treat Autism Spectrum Disorder. The government has made it clear that the therapeutic use of any type of stem cell for autism is not approved as routine or standard clinical treatment.
Stem cell interventions involving autism may be undertaken only as part of duly approved clinical trials. These studies must follow the National Guidelines for Stem Cell Research, 2017, jointly issued by the Indian Council of Medical Research and the Department of Biotechnology.
Important conditions include:
Stem cell therapy for autism must remain restricted to authorised clinical trials.
The clinical trial must receive all necessary regulatory and ethics approvals.
Clinics cannot market experimental autism interventions as routine medical services.
Doctors cannot claim that stem cells are an established cure for autism.
Parents and caregivers should confirm a trial’s official registration and approvals before considering participation.
The advisory does not prohibit legitimate research but requires it to be conducted under approved clinical-trial safeguards.
NMC warns doctors against unauthorised practices
The National Medical Commission has reinforced the regulatory position through its advisory dated September 5, 2026. It has warned registered medical practitioners against administering, prescribing, recommending, promoting or advertising stem cell therapies for unapproved indications.
The NMC has stated that involvement in unauthorised stem cell treatment could amount to professional misconduct. State Medical Councils have been advised to examine complaints and initiate disciplinary proceedings when violations are established after due process.
The NMC directions cover the following actions:
Administering stem cell therapy for an indication that has not been approved.
Prescribing an experimental intervention as standard treatment.
Promoting unproven therapies through websites, social media or advertisements.
Making unsupported claims about guaranteed recovery or a permanent cure.
Commercially offering stem cell therapy outside an authorised clinical trial.
Failing to properly explain the experimental status and potential risks to patients.
Supreme Court judgment prompted stronger enforcement
The Health Ministry’s advisory follows the Supreme Court’s January 30, 2026 judgment in Yash Charitable Trust and Others versus Union of India and Others. The ruling emphasised that failure to comply with the statutory framework governing stem cell therapy must result in appropriate consequences.
The advisory reminds authorities that the existence of scientific research into stem cells does not permit clinics to sell unapproved interventions. Every therapeutic use must comply with the approved framework, and experimental research must remain within regulated clinical trials.
The judgment and subsequent advisory underline that:
Unapproved stem cell interventions cannot be treated as ordinary medical services.
Regulatory violations must result in meaningful action.
Medical professionals can be investigated for professional misconduct.
Clinical establishments may face penalties or loss of registration.
State authorities are responsible for enforcing the rules at the local level.
Penalties for violating stem cell therapy rules
Doctors found responsible for unauthorised stem cell therapy may face professional-misconduct proceedings under Regulation 7.22 of the Indian Medical Council Regulations, 2002. Any disciplinary action must be taken after examining the evidence and following the required legal process.
Clinical establishments may separately face action under Sections 32 and 40 of the Clinical Establishments Registration and Regulation Act, 2010. Depending on the nature of the violation, this can include financial penalties and cancellation of registration.
Possible consequences include:
Professional-misconduct proceedings against registered medical practitioners.
Disciplinary action by State Medical Councils.
Investigation of hospitals and clinics offering unauthorised treatments.
Penalties under the Clinical Establishments Act.
Cancellation of a clinical establishment’s registration in applicable cases.
Action against misleading promotion or advertisement of unproven therapies.
What patients and families should verify
Patients should not assume that every treatment described as “stem cell therapy” is approved, safe or clinically effective. Before agreeing to any such intervention, they should consult a qualified specialist and verify whether the proposed treatment is authorised for their medical condition.
Patients and families should check:
Whether the proposed stem cell treatment is approved for the diagnosed condition.
Whether it is being offered as standard treatment or as part of a clinical trial.
Whether the clinical trial has valid regulatory and ethics approvals.
Whether the trial is officially registered and provides proper informed-consent documents.
Whether the treating doctor and clinical establishment are appropriately registered.
Whether the clinic is making unsupported claims of guaranteed improvement or cure.
Whether the risks, possible benefits, alternatives and experimental status have been clearly explained.
The advisory’s central message is that stem cell science may hold research potential, but unproven interventions must not be sold as established treatment. Patients should rely on approved medical care and independently verify regulatory claims before making decisions.
Moderna and Merck announced positive late-stage melanoma trial results on Wednesday, August 19. The Phase 3 study involved 1,137 patients with surgically removed high-risk stage IIB to IV melanoma.
Moderna Cancer Vaccine meets key Phase 3 melanoma goals
Moderna and Merck have reported a major clinical milestone for their personalised mRNA cancer therapy after the Phase 3 INTerpath-001 trial met its primary and key secondary endpoints in patien
Moderna and Merck announced positive late-stage melanoma trial results on Wednesday, August 19. The Phase 3 study involved 1,137 patients with surgically removed high-risk stage IIB to IV melanoma.
Moderna Cancer Vaccine meets key Phase 3 melanoma goals
Moderna and Merck have reported a major clinical milestone for their personalised mRNA cancer therapy after the Phase 3 INTerpath-001 trial met its primary and key secondary endpoints in patien
